Warfarin |
Coumadin; Jantoven |
Clinical Trial: SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism
This study is no longer recruiting patients.
|
Purpose
Patients who have a pulmonary embolism (blood clot in the lung) will be treated in this study. The purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood-thinning) drug, SR34006, with the standard way of treating a pulmonary embolism. The standard treatment includes injections or infusions of an anticoagulant drug, (LMW)heparin, for about a week followed by anticoagulant tablets (warfarin or acenocoumarol) which are taken by mouth.
Assignment to either SR34006 or (LMW)heparin plus warfarin or acenocoumarol will be purely by chance and will be known by both patients and their doctors.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Pulmonary Embolism | Drug: SR34006 Drug: (LMW)heparin Drug: Warfarin VKA Drug: Acenocoumarol VKA | Phase III |
MedlinePlus related topics: Pulmonary Embolism
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Safety/Efficacy Study
Official Title: The Van Gogh-PE trial, a Multicenter, International, Randomized, Open-label, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous SR34006 with the Combination of (LMW)Heparin and Vitamin K Antagonist (VKA) in the Treatment of Acute Symptomatic Pulmonary Embolism
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Confirmed acute symptomatic Pulmonary Embolism (PE) with or without concomitant Deep Vein Thrombosis (DVT)
- Written informed consent
Exclusion Criteria:
- Legal lower age limitations (country specific)
- Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of PE
- Other indication for VKA than PE/DVT
- More than 36 hours pre-randomization treatment with therapeutic dosages of (LMW)heparin or initiation of VKA treatment prior to randomization
- Participation in another pharmacotherapeutic study within the prior 30 days
- Creatinine clearance <10 mL/min, severe hepatic disease, or bacterial endocarditis
- Life expectancy <3 months
- Active bleeding or high risk for bleeding
- Uncontrolled hypertension: systolic blood pressure >180 mm Hg or diastolic blood pressure >110 mm Hg
- Pregnancy or childbearing potential without proper contraceptive measures or women who are breastfeeding
- Any other contraindication listed in the labeling of warfarin, acenocoumarol, unfractionated heparin, enoxaparin, or tinzaparin
Location Information
California
University of California, San Diego Medical Center, San Diego, California, United States
Jerry L. Pettic VA Medical Center, Loma Linda, California, United States
Colorado
University of Colorado Hospital, Denver, Colorado, United States
Anschutz Cancer Pavilion, Aurora, Colorado, United States
Florida
Brandon Regional Hospital, Brandon, Florida, 33511, United States
Bay Pines VA Medical Center, Bay Pines, Florida, 33744, United States
Holmes Regional Medical Center, Melbourne, Florida, 32901, United States
St. Joseph's Hospital, Tampa, Florida, 33607, United States
Jackson Memorial Hospital, Miami, Florida, 33136, United States
Georgia
DeKalb Medical Center, Decatur, Georgia, 30033, United States
Medical College of Georgia, Augusta, Georgia, 30912, United States
Illinois
Loyola University Medical Center and Outpatient Clinic, Maywood, Illinois, 60153, United States
Kansas
Olathe Medical Center, Olathe, Kansas, United States
Louisiana
Christus St. Patrick Hospital, Lake Charles, Louisiana, 70601, United States
Maryland
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
Massachusetts
Baystate Medical Center, Springfield, Massachusetts, 01199, United States
Boston Medical Center, Boston, Massachusetts, United States
Michigan
William Beaumont Hospital, Troy, Michigan, 48085, United States
St. Joseph Mercy - Oakland, Pontiac, Michigan, 48341, United States
William Beaumont Hospital, Royal Oak, Michigan, 48073, United States
Henry Ford Hospital, Detroit, Michigan, 48202, United States
New Mexico
Lovelace Health Systems, Clinical Thrombosis Center, Albuquerque, New Mexico, 87108, United States
New York
Mount Sinai School of Medicine, New York, New York, United States
Winthrop University Hospital, Mineola, New York, 11501, United States
Winthrop Pulmonary Associates, Mineola, New York, 11501, United States
St. Luke's-Roosevelt Hospital Center, New York, New York, United States
North Carolina
University of North Carolina Hospitals, Chapel Hill, North Carolina, 27599, United States
North Dakota
Altru Health System Hospital, Grand Forks, North Dakota, 58201, United States
Ohio
Riverside Methodist Hospital, Columbus, Ohio, 43214, United States
Akron General Medical Center, Akron, Ohio, 44307, United States
Medical College of Ohio, Toledo, Ohio, 43614, United States
Oklahoma
INTEGRIS Southwest Medical Center, Oklahoma City, Oklahoma, 73109, United States
Saint Anthony Hospital, Oklahoma City, Oklahoma, 73101, United States
OU Medical Center, Oklahoma City, Oklahoma, 73104, United States
Oklahoma City VA Medical Center, Oklahoma City, Oklahoma, 73104, United States
Pennsylvania
Crozer-Chester Medical Center, Upland, Pennsylvania, 19013, United States
Lehigh Valley Hospital, Allentown, Pennsylvania, 18105, United States
South Carolina
Mary Black Memorial Hospital, Spartanburg, South Carolina, 29307, United States
Spartanburg Regional Medical Center, Spartanburg, South Carolina, 23903, United States
Tennessee
Baptist Memorial Hospital Memphis, Memphis, Tennessee, United States
The West Cancer Clinic, Memphis, Tennessee, United States
Texas
Scott & White Memorial Hospital & Clinic, Temple, Texas, 76508, United States
Northwest Texas Healthcare System, Amarillo, Texas, 79106, United States
The Methodist Hospital, Houston, Texas, 77030, United States
The University of Texas Health Center at Tyler, Tyler, Texas, 75708, United States
Utah
University Hospital, Salt Lake City, Utah, United States
Virginia
McGuire VA Medical Center, Richmond, Virginia, 23249, United States
Inova Alexandria Hospital, Alexandria, Virginia, 22304, United States
Pulmonary Associates of Fredericksburg, Inc., Fredericksburg, Virginia, United States
Portsmouth Pulmonary Associates, Chesapeake, Virginia, United States
Maryview Medical Center, Portsmouth, Virginia, United States
MedSource, Inc., Chesapeake, Virginia, United States
Washington
Swedish Medical Center, Seattle, Washington, 98122, United States
Sacred Heart Medical Center, Spokane, Washington, 99220, United States
Argentina
Buenos Aires, Argentina
Australia
Box Hill, Clayton, Garran, Kogarah, Ringwood East, Australia
St. Leonards, South Australia, Australia
Austria
Graz, Austria
Belgium
Bruxelles, Charleroi, Leuven, Liege, Yvoir, Belgium
Brazil
Goiania, Porto Alegre, Sao Paulo, Salvador, Brazil
Canada, Alberta
University of Alberta Hospital, Edmonton, Alberta, T6G 2B7, Canada
Canada, British Columbia
Kelowna General Hospital, Kelowna, British Columbia, V1Y 1T2, Canada
St. Paul's Hospital, Vancouver, British Columbia, Canada
Canada, Manitoba
St. Boniface General Hospital, Winnipeg, Manitoba, R2H 2A6, Canada
Canada, Nova Scotia
QEII Health Sciences Center, Halifax, Nova Scotia, B3H 2Y9, Canada
Canada, Ontario
London Health Sciences Centre, London, Ontario, N6A 4G5, Canada
Ottawa Hospital - Civic Campus, Ottawa, Ontario, K1Y 4E9, Canada
Hamilton Health Sciences - General Hospital, Hamilton, Ontario, Canada
University Health Network, Toronto General Hospital, Toronto, Ontario, Canada
Humber River Regional Hospital, Weston, Ontario, Canada
Canada, Quebec
Jewish General Hospital, Montreal, Quebec, Canada
Hotel-Dieu de St-Jerome, St-Jerome, Quebec, Canada
Czech Republic
Brno, Jihlava, Karlovy Vary, Kladno, Ostrava Poruba, Prague, Czech Republic
Plzen, Czech Republic
Denmark
Arhus, Frederiksberg, Glostrup, Hillerod, Kobenhavn, Odense, Denmark
Roskilde, Denmark
Finland
Hus, Jyvaskyla, Seinajoki, Turku, Finland
France
Armentieres, Besancon, Bethune, Brest, Chambray Les Tours, France
Clamart, Lens, Lille, Nice, Nimes, Paris, Rennes, Roubaix, France
Saint Malo, Valenciennes, France
Tourcoing, France
Germany
Augsburg, Berlin, Bochum, Dresden, Garmisch-Partenkirchen, Germany
Heidelberg, Ibbenburen, Mannheim, Munchen, Germany
Italy
Cremona, Fidenza, Genova, Lecco, Milano, Padova, Parma, Pavia, Italy
Piacenza, Pisa, Reggio Emilia, Treviso, Venezia, Italy
Netherlands
Alkmaar, Amersfoort, Amsterdam, Breda, Gouda, Groningen, Netherlands
Haarlem, Maastricht, Nieuwegein, Netherlands
Norway
Oslo, Rud, Norway
Poland
Lublin, Warszawa, Wroclaw, Poland
Spain
Badalona, Madrid, Sevilla, Spain
Sweden
Goteborg, Jonkoping, Stockholm, Varnamo, Sweden
Switzerland
Basel, Bern, Lugano, Switzerland
United Kingdom
London, United Kingdom
More Information
http://www.sanofi-synthelabo.us
Record last reviewed: February 2005
Last Updated: February 4, 2005
Record first received: June 16, 2003
ClinicalTrials.gov Identifier: NCT00062803
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Not Signed In -


